OBJECTIVE: Viral load testing is used in the HIV programme of Chiradzulu, Malawi, to confirm the diagnosis of immunological failure to prevent unnecessary switching to second-line therapy. Our objective was to quantify the benefit of this strategy for management of treatment failure in a large decentralized HIV programme in Africa. METHODS: Retrospective analysis of monitoring data from adults treated with first-line antiretroviral regimens for >1 year and meeting the WHO immunological failure criteria in an HIV programme in rural Malawi. The positive predictive value of using immunological failure criteria to diagnose virological failure (viral load >5000 copies/ml) was estimated. RESULTS: Of the 227 patients with immunological failure (185 confirmed with a repeat CD4 measurement), 155 (68.2%) had confirmatory viral load testing. Forty-four (28.4%) had viral load >5000 copies/ml and 57 (36.8%) >1000 copies/ml. Positive predictive value was 28.4% (95% CI 21.4-36.2%). Repeat CD4 count testing showed that 41% of patients initially diagnosed with immunological failure did no longer meet failure criteria. CONCLUSIONS: Our results support the need for confirming all cases of immunological failure with viral load testing before switching to second-line ART to optimize the use of resources in developing countries.
OBJECTIVE: Viral load testing is used in the HIV programme of Chiradzulu, Malawi, to confirm the diagnosis of immunological failure to prevent unnecessary switching to second-line therapy. Our objective was to quantify the benefit of this strategy for management of treatment failure in a large decentralized HIV programme in Africa. METHODS: Retrospective analysis of monitoring data from adults treated with first-line antiretroviral regimens for >1 year and meeting the WHO immunological failure criteria in an HIV programme in rural Malawi. The positive predictive value of using immunological failure criteria to diagnose virological failure (viral load >5000 copies/ml) was estimated. RESULTS: Of the 227 patients with immunological failure (185 confirmed with a repeat CD4 measurement), 155 (68.2%) had confirmatory viral load testing. Forty-four (28.4%) had viral load >5000 copies/ml and 57 (36.8%) >1000 copies/ml. Positive predictive value was 28.4% (95% CI 21.4-36.2%). Repeat CD4 count testing showed that 41% of patients initially diagnosed with immunological failure did no longer meet failure criteria. CONCLUSIONS: Our results support the need for confirming all cases of immunological failure with viral load testing before switching to second-line ART to optimize the use of resources in developing countries.
Authors: Julia K Rohr; Prudence Ive; Charles Robert Horsburgh; Rebecca Berhanu; Christopher J Hoffmann; Robin Wood; Andrew Boulle; Janet Giddy; Hans Prozesky; Michael Vinikoor; Mwanza Wa Mwanza; Gilles Wandeler; Mary-Ann Davies; Matthew P Fox Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Man Po Lee; Cuong Duy Do; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: AIDS Care Date: 2017-01-29
Authors: Randy G Mungwira; Titus H Divala; Osward M Nyirenda; Maxwell Kanjala; Francis Muwalo; Felix A Mkandawire; Augustine Choko; Terrie E Taylor; Jane Mallewa; Joep J van Oosterhout; Miriam K Laufer; Matthew B Laurens Journal: Trop Med Int Health Date: 2018-03-30 Impact factor: 2.622
Authors: Kate El Bouzidi; Fati Murtala-Ibrahim; Vivian Kwaghe; Rawlings P Datir; Obinna Ogbanufe; Trevor A Crowell; Man Charurat; Patrick Dakum; Ravindra K Gupta; Nicaise Ndembi; Caroline A Sabin Journal: J Acquir Immune Defic Syndr Date: 2022-05-01 Impact factor: 3.771
Authors: Denise H Evans; Matthew P Fox; Mhairi Maskew; Lynne McNamara; Patrick MacPhail; Christopher Mathews; Ian Sanne Journal: J Int AIDS Soc Date: 2014-09-15 Impact factor: 5.396